News
July 31, 2020
Help Us Support Feeding America
Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.
June 22, 2020
Second indication for Tazverik™
TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.
May 13, 2020
RETEVMO™ (selpercatinib)
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
April 20, 2020
Tukysa™ (tucatinib)
Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
April 13, 2020
Koselugo (selumetinib)
Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
March 13, 2020
Covid-19 Update For Patients
In response to the current COVID-19 situation, we’ve examined all areas of our business and pharmacy operations at every Onco360 location across the country and have taken actions to ensure continued service to our patients and their caregivers.
March 6, 2020
Onco360 Safety Awareness
Onco360 is aware of the emergence of the new coronavirus (COVID-19) illness and is closely monitoring the situation and possible future impact.
January 24, 2020
Tazverik™ (tazemetostat)
Onco360 has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK™ (tazemetostat), a new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.